In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 EMAIL TO FRIEND     |      PRINTER FRIENDLY     |    
          advertisement

Genetic Breakthrough Spells Hope for Lung Fibrosis Patients

July 8 (HealthDay News) -- Genes that can help doctors predict when patients with idiopathic pulmonary fibrosis are becoming seriously ill have been identified by U.S. researchers, who said the findings might help keep patients alive until they can get a lung transplant.

Idiopathic pulmonary fibrosis (IPF) is a lung-scarring disease that progresses slowly and causes a gradual decline in lung function. There is no cure or effective treatment for IPF, and median survival is about three years. However, some patients experience a more rapid deterioration.

"Approximately 10 percent of patients develop an acute phase that in most cases is lethal," senior study author Dr. Naftali Kaminski said in a news release. She is director of the interstitial lung diseases center at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center.

In a study designed to learn more about the molecular mechanisms of accelerated IPF, the researchers compared the gene activity profile of the lungs of eight IPF patients who were experiencing dramatic worsening of their disease when they died, 23 stable IPF patients and 15 people with healthy lungs.

Differences in the expression of nearly 600 genes were noted between IPF patients with accelerated disease and those with stable disease. The researchers found no evidence that infection or inflammation was the cause of accelerated IPF. They did find signs that the cells of the alveolar epithelium, the tissue that covers the surface of the lung's air sacs, were rapidly dying.

"That could mean that drugs that are used to protect the epithelium in other illnesses, such as cancer, might help IPF patients survive an exacerbation. If we can keep them alive, there's a chance they could get a lifesaving lung transplant," study co-author Dr. Kevin Gibson, an associate professor in the pulmonary, allergy and critical care medicine division at the University of Pittsburgh School of Medicine and medical director of the interstitial lung diseases center, said in the release from the school.

The study appears in the July 15 issue of the American Journal of Respiratory and Critical Care Medicine.


SOURCE: University of Pittsburgh Schools of Public Health, news release, July 7, 2009

advertisement

Advice from Dr. Nancy Snyderman

Dr. Nancy Snyderman

Helpful tips and information on weight loss

Get answers from an expert
advertisement

YourTotalHealth      

Home  |  Health Centers  |  Health A-Z  |  Staying Healthy  |  Diet & Fitness  |  Woman & Family  |  Pregnancy  |  Community  |  

also on iVillage: Pregnancy & Parenting  |  Beauty & Style  |  Home & Garden  |  Food  |  Weddings  |  Love  |  Entertainment  |  NeverSayDiet

Terms of Service  |  Privacy Policy  |  Site Map  |  Newsletters  |  Feedback

Copyright (c) 2000-2009 iVillage Inc. All rights reserved. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.